On Wednesday, Shares of Marathon Oil Corporation (NYSE:MRO), lost -7.15% to $16.23, hitting its lowest level, as oil futures dropped toward $40 a barrel on Wednesday to settle with a loss of more than 4% after a U.S. government stated an unpredictable weekly climb in crude-oil inventories, according to Market Watch.
Crude oil for delivery in September settled at $40.80 a barrel, down $1.82, or 4.3% on the New York Mercantile Exchange, with prices marking their lowest settlement since March 2, 2009. The September contract expires Thursday.
Marathon Oil Corporation operates as an energy company. It operates in three segments: North America Exploration and Production, International Exploration and Production, and Oil Sands Mining.
Shares of Yahoo! Inc. (NASDAQ:YHOO), declined -1.40% to $35.19, during its last trading session.
Yahoo’s 2015 earnings estimates were lowered to $0.18 from $0.37 per share at Cantor Fitzgerald, with 2016 earnings estimates cut to $0.31 from $0.43 per share.
The firm maintained its “buy” rating and $56 price target on the stock.
Cantor Fitzgerald noted that they lowered the price target to reflect their adjustment to Alibaba’s (BABA) price target to $95 from $110.
Yahoo! declared plans earlier this year to spin off its stake in Alibaba into an independent investment company called Aabaco Holdings, Inc.
Also, the firm noted that to match today’s Yahoo! share price, Alibaba’s spin off needs to be taxed at 38%, and no further upside in Alibaba’s share price would be predictable.
Yahoo! Inc. provides search and display advertising services on Yahoo properties and associate sites worldwide. The company offers Yahoo Search that serves as a starting point to navigate the Internet and discover information; and Yahoo Answers, which enables users to seek, discover, and share knowledge and opinions across mobile phones, tablets, and desktops.
Finally, Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), ended its last trade with -1.01% loss, and closed at $15.63.
Inotek Pharmaceuticals Corporation declared the closing of its formerly declared public offering of 5,400,000 shares of its common stock at a public offering price of $12.75 per share, before underwriting discounts. In addition, the underwriters have fully exercised their option to purchase an additional 810,000 shares of common stock. Gross proceeds from the offering of an aggregate of 6,210,000 shares, before underwriting discounts and commissions and offering expenses were about $79.2 million. Inotek plans to use the net proceeds from this offering to fund the continued development of its product candidates and for other general corporate purposes.
Cowen and Company, Piper Jaffray & Co. and Nomura Securities International, Inc. are acting as joint book-running managers for the offering.
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
